In our study, we investigate whether ERα and PR expression predicts risk of disease recurrence and if it has any associations with clinicopathologic factors, histologic patterns, mutation status, or immune factors in stage I lung adenocarcinoma patients. This evidence concerns the gene PGR and lung adenocarcinoma.